Loading...

PerCP/Cyanine5.5 anti-mouse I-A/I-E Antibody

Pricing & Availability
Clone
M5/114.15.2 (See other available formats)
Regulatory Status
RUO
Other Names
MHC class II
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
M5-114-15-2_PerCPCyanine55_I-A-I-E_Antibody_101618
C57BL/6 mouse splenocytes were stained with CD45R/B220 APC and I-A/I-E (clone M5/114.15.2) PerCP/Cyanine5.5 (left), or rat IgG2b, κ PerCP/Cyanine5.5 isotype control (right).
  • M5-114-15-2_PerCPCyanine55_I-A-I-E_Antibody_101618
    C57BL/6 mouse splenocytes were stained with CD45R/B220 APC and I-A/I-E (clone M5/114.15.2) PerCP/Cyanine5.5 (left), or rat IgG2b, κ PerCP/Cyanine5.5 isotype control (right).
Compare all formats See PerCP/Cyanine5.5 spectral data
Cat # Size Price Save
107625 25 µg ¥21,010
107626 100 µg ¥57,500
Description

These class II molecules are expressed on antigen presenting cells (including B cells) and a subset of T cells from H-2b,d,q,r bearing mice and are involved in antigen presentation to T cells expressing CD3/TCR and CD4 proteins.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Activated C57BL/6 mouse spleen cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is =0.06 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Application Notes

The M5/114.15.2 antibody reacts with a polymorphic determinant shared by the I-Ab, I-Ad, I-Aq, I-Ed, and I-Ek MHC class II alloantigens from mice carrying H-2p,r,q,b,d,u haplotypes. Clone M5/114.15.2 however does not react wtih I-Af, I-Ak, or I-As MHC class II alloantigens.1

Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunohistochemistry of frozen sections2,3,6, in vitro and in vivo blocking of antigen presentation or ligand binding4-7, and spatial biology (IBEX)17,18. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 107655 & 107656).

Application References

(PubMed link indicates BioLegend citation)
  1. Bhattacharya A, et al. 1981. J. Immunol. 127:2488. (IP)
  2. Viville S, et al. 1993. Cell 72:635. (IHC)
  3. Nelson AJ, et al. 1993. J. Immunol. 151:2453. (IHC)
  4. Shi Y, et al. 1998. J. Exp. Med. 187:367. (Block)
  5. Yamashita I, et al. 1993. Int. Immunol. 5:1139.
  6. Guo M, et al. 1995. Zygote 3:65. (IHC)
  7. Kim A, et al. 2004. Exp. Mol. Med. 36:428. (Block)
  8. Luckashenak NA, et al. 2006. J. Immunol. 177:5177.
  9. Venanzi ES, et al. 2007. J. Immunol. 179:5693.
  10. Christensen SR, et al. 2006. Immunity 25:417. PubMed
  11. Matte-Martone C, et al. 2008. Blood 111:3884. PubMed
  12. De Pascalis R, et al. 2008. Infect. Immun. 76:4311. PubMed
  13. Kuns RD, et al. 2009. Blood 113:5999. PubMed
  14. Sabatino JJ, et al. 2011. J. Exp. Med. 208:81. PubMed
  15. Draber P, et al. 2011. Mol Cell Biol. 22:4550. PubMed
  16. Fu H, et al. 2014. Nat Commun. 5:3436. PubMed
  17. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  18. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Liu Z, et al. 2022. Cancer Commun (Lond). 42:971. PubMed
  2. Zhu J, et al. 2022. Research (Wash D C). 2022:9816272. PubMed
  3. Lombard-Vadnais F, et al. 2023. iScience. 26:105852. PubMed
  4. Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed
  5. Arruda DC, et al. 2022. J Control Release. 350:228. PubMed
  6. Ho HM, et al. 2022. Pharmaceutics. 14:. PubMed
  7. Chen R, et al. 2023. Acta Pharm Sin B. 13:128. PubMed
  8. Cozzolino M, et al. 2023. Int J Mol Sci. 24:. PubMed
  9. He Q, et al. 2023. Parasit Vectors. 16:139. PubMed
  10. Seclì L, et al. 2023. J Immunother Cancer. 11:. PubMed
  11. Griffin GK, et al. 2023. Nature. 618:834. PubMed
  12. Pitzer Mutchler A, et al. 2023. Front Physiol. 14:1167904. PubMed
  13. Ortiz G, et al. 2020. Front Immunol. 11:1713. PubMed
  14. Herz J, et al. 2015. J Exp Med. 212: 1153 - 1169. PubMed
  15. Matsumoto R, et al. 2021. Front Pharmacol. 12:715752. PubMed
  16. Kong D, et al. 2022. J Heart Lung Transplant. Online ahead of print. PubMed
  17. Nakamura M, et al. 2015. J Immunol. 194:243. PubMed
  18. Gonçalves NP, et al. 2017. J Neuroinflammation. 14:115. PubMed
  19. Rao E, et al. 2021. Sci Immunol. 6:. PubMed
  20. Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed
  21. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  22. Gounder AP, et al. 2018. PLoS Pathog. 14:e1007001. PubMed
  23. Li S, et al. 2021. Ann Transl Med. 9:1644. PubMed
  24. Volkov A, et al. 2013. PLoS One. 8:60565. PubMed
  25. Okuniewska M, et al. 2021. Cell Reports. 36(2):109368. PubMed
  26. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  27. Zhuang Z, et al. 2021. J Exp Med. 218:00:00. PubMed
  28. Sharma S, et al. 2015. J Immunol. 194:5529. PubMed
  29. Sharma PK, et al. 2018. Cancer Gene Ther. 25:27. PubMed
  30. Fantauzzi MF, et al. 2021. ERJ Open Res. 7: . PubMed
  31. Pello O, et al. 2012. PLoS One. 7:e45399. PubMed
  32. Vijay R, et al. 2015. J Exp Med. 212: 1851 - 1868. PubMed
  33. Liang Z, et al. 2020. Pain. 161:2089. PubMed
  34. Terashima Y, et al. 2020. Nat Commun. 11:609. PubMed
  35. Funk KE, et al. 2019. J Neuroinflammation. 16:22. PubMed
  36. Wang J, et al. 2021. Nat Commun. 12:6198. PubMed
  37. Donati Y, et al. 2020. Am J Physiol Lung Cell Mol Physiol. L619:318. PubMed
  38. Grzelak A, et al. 2018. Int J Mol Sci. 19:. PubMed
  39. Codina A, et al. 2019. Cell Syst. 8:136. PubMed
  40. McFarlane AJ, et al. 2017. J Allergy Clin Immunol. 140:1068. PubMed
  41. Dobosz E, et al. 2021. Dis Model Mech. :14. PubMed
  42. Xue N, et al. 2017. Sci Rep. 7:39011. PubMed
  43. Yang Y, et al. 2021. Sci Adv. 7:eabf6290. PubMed
  44. Zhang Q, et al. 2022. Nat Commun. 13:2406. PubMed
  45. Nishida J, et al. 2022. STAR Protoc. 3:101306. PubMed
  46. Fidalgo MF, et al. 2022. Life Sci Alliance. 5:. PubMed
  47. Bartmann J, et al. 2016. Int Immunol. 28: 473 - 487. PubMed
  48. Ji DX, et al. 2019. Nat Microbiol. 1.644444444. PubMed
  49. Rozanski C, et al. 2015. J Immunol. 194:4717. PubMed
  50. Movahedi K, et al. 2012. Cancer Res. 74:4165. PubMed
  51. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
  52. Fu Y, et al. 2021. Front Cell Dev Biol. 9:689727. PubMed
  53. Georgoudaki A, et al. 2016. Cell Rep. 15: 2000-2011. PubMed
  54. Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed
  55. Yi H, et al. 2021. Front Immunol. 12:719189. PubMed
  56. Clement CC, et al. 2021. Immunity. 54:721. PubMed
  57. Bent EH, et al. 2021. Nat Commun. 12:6218. PubMed
  58. Zhang MS, et al. 2022. Nat Commun. 13:954. PubMed
  59. Walker MT, et al. 2021. Front. Allergy. 2:. PubMed
  60. Lu X, et al. 2019. Circ Res. 125:1055. PubMed
  61. Bell CR, et al. 2022. Nat Commun. 13:2063. PubMed
  62. Alhudaithi SS, et al. 2020. Mol Pharm. 17:4691. PubMed
  63. Kiss M, et al. 2020. Cancer Immunol Res. 9:309. PubMed
  64. Mairhofer D, et al. 2015. J Invest Dermatol. 135: 2785-93. PubMed
  65. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  66. Aguilar-Pimentel A, et al. 2017. PLoS One. 12(6):e0178563. PubMed
  67. Lau P, et al. 2022. Cell Mol Immunol. :. PubMed
  68. Hildreth AD, et al. 2020. STAR Protoc. 1:100113. PubMed
  69. Golabek A, et al. 2021. Exp Ther Med. 21:482. PubMed
  70. Chen R, et al. 2021. Front Oncol. 11:743050. PubMed
  71. Stack G, et al. 2015. PLoS Pathog. 11:1004641. PubMed
  72. Lai NY, et al. 2020. Cell. 180:33:00. PubMed
  73. Andreata F, et al. 2021. STAR Protoc. 2:100831. PubMed
  74. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  75. Li J, et al. 2021. eLife. 10:00. PubMed
  76. Chng S, et al. 2016. Sci Rep. 6: 23820. PubMed
RRID
AB_2191071 (BioLegend Cat. No. 107625)
AB_2191071 (BioLegend Cat. No. 107626)

Antigen Details

Structure
MHC class II
Distribution

B cell and activated T cells, APCs of the H-2b,d,q,r bearing mice

Function
Antigen presentation
Ligand/Receptor
CD3/TCR, CD4
Cell Type
Antigen-presenting cells, B cells, Dendritic cells, T cells, Tregs
Biology Area
Immunology, Innate Immunity
Molecular Family
MHC Antigens
Antigen References

1. Watts C. 1997. Ann. Rev. Immunol. 15:821.
2. Pamer E, et al. 1998. Ann. Rev. Immunol. 16:323.

Gene ID
14961 View all products for this Gene ID 14969 View all products for this Gene ID
UniProt
View information about I-A/I-E on UniProt.org

Related FAQs

How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?

PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.

Other Formats

View All I-A/I-E Reagents Request Custom Conjugation
Description Clone Applications
Biotin anti-mouse I-A/I-E M5/114.15.2 FC
FITC anti-mouse I-A/I-E M5/114.15.2 FC
PE anti-mouse I-A/I-E M5/114.15.2 FC
Purified anti-mouse I-A/I-E M5/114.15.2 FC,IHC-F,IP,Block
PE/Cyanine5 anti-mouse I-A/I-E M5/114.15.2 FC
APC anti-mouse I-A/I-E M5/114.15.2 FC
Alexa Fluor® 488 anti-mouse I-A/I-E M5/114.15.2 FC,3D IHC
Alexa Fluor® 647 anti-mouse I-A/I-E M5/114.15.2 FC
Pacific Blue™ anti-mouse I-A/I-E M5/114.15.2 FC
Alexa Fluor® 700 anti-mouse I-A/I-E M5/114.15.2 FC,SB
PerCP/Cyanine5.5 anti-mouse I-A/I-E M5/114.15.2 FC
PerCP anti-mouse I-A/I-E M5/114.15.2 FC
APC/Cyanine7 anti-mouse I-A/I-E M5/114.15.2 FC
PE/Cyanine7 anti-mouse I-A/I-E M5/114.15.2 FC
Brilliant Violet 421™ anti-mouse I-A/I-E M5/114.15.2 FC,IHC-F,SB
Brilliant Violet 510™ anti-mouse I-A/I-E M5/114.15.2 FC
Purified anti-mouse I-A/I-E (Maxpar® Ready) M5/114.15.2 FC,CyTOF®
Brilliant Violet 605™ anti-mouse I-A/I-E M5/114.15.2 FC
Brilliant Violet 650™ anti-mouse I-A/I-E M5/114.15.2 FC
Brilliant Violet 711™ anti-mouse I-A/I-E M5/114.15.2 FC
Brilliant Violet 785™ anti-mouse I-A/I-E M5/114.15.2 FC
PE/Dazzle™ 594 anti-mouse I-A/I-E M5/114.15.2 FC
Alexa Fluor® 594 anti-mouse I-A/I-E M5/114.15.2 IHC-F,3D IHC
APC/Fire™ 750 anti-mouse I-A/I-E M5/114.15.2 FC
TotalSeq™-A0117 anti-mouse I-A/I-E M5/114.15.2 PG
Ultra-LEAF™ Purified anti-mouse I-A/I-E M5/114.15.2 FC,IHC-F,IP,Block
TotalSeq™-B0117 anti-mouse I-A/I-E M5/114.15.2 PG
TotalSeq™-C0117 anti-mouse I-A/I-E M5/114.15.2 PG
Spark Blue™ 550 anti-mouse I-A/I-E M5/114.15.2 FC
PE/Fire™ 640 anti-mouse I-A/I-E M5/114.15.2 FC
Spark YG™ 581 anti-mouse I-A/I-E M5/114.15.2 FC
PE/Fire™ 810 anti-mouse I-A/I-E M5/114.15.2 FC
Spark UV™ 387 anti-mouse I-A/I-E M5/114.15.2 FC
Spark Violet™ 538 anti-mouse I-A/I-E M5/114.15.2 FC
PerCP/Fire™ 806 anti-mouse I-A/I-E M5/114.15.2 FC
Spark Red™ 718 anti-mouse I-A/I-E M5/114.15.2 FC
APC/Fire™ 810 anti-mouse I-A/I-E M5/114.15.2 FC
Spark PLUS UV395™ anti-mouse I-A/I-E M5/114.15.2 FC
Go To Top Version: 4    Revision Date: 10/30/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account